RGL-2201

RGL-2201 is an investigational gene therapy developed by Shanghai Regenelead Therapies for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and choroidal neovascularization. It is a biological product administered via injection, currently in Phase 1 clinical trials. The therapy aims to address abnormal blood vessel growth in the eye, which characterizes these conditions. The precise molecular target or transgene has not been disclosed publicly, but its classification as a gene therapy suggests it delivers genetic material to modify disease processes associated with ocular neovascularization[1][2].